Literature DB >> 2001747

Studies on the role of the S4 substrate binding site of HIV proteinases.

J Tözsér1, A Gustchina, I T Weber, I Blaha, E M Wondrak, S Oroszlan.   

Abstract

Kinetic analysis of the hydrolysis of the peptide H-Val-Ser-Gln-Asn-Tyr*Pro-Ile-Val-Gln-NH2 and its analogs obtained by varying the length and introducing substitutions at the P4 site was carried out with both HIV-1 and HIV-2 proteinases. Deletion of the terminal Val and Gln had only moderate effect on the substrate hydrolysis, while the deletion of the P4. Ser as well as P'3 Val greatly reduced the substrate hydrolysis. This is predicted to be due to the loss of interactions between main chains of the enzyme and the substrate. Substitution of the P4 Ser by amino acids having high frequency of occurrence in beta turns resulted in good substrates, while large amino acids were unfavorable in this position. The two proteinases acted similarly, except for substrates having Thr, Val and Leu substitutions, which were better accommodated in the HIV-2 substrate binding pocket.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2001747     DOI: 10.1016/0014-5793(91)80186-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  26 in total

1.  Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.

Authors:  Deborah S Dauber; Rainer Ziermann; Neil Parkin; Dustin J Maly; Sami Mahrus; Jennifer L Harris; Jon A Ellman; Christos Petropoulos; Charles S Craik
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  A comparative study of HIV-1 and HTLV-I protease structure and dynamics reveals a conserved residue interaction network.

Authors:  Pia Rücker; Anselm H C Horn; Heike Meiselbach; Heinrich Sticht
Journal:  J Mol Model       Date:  2011-01-29       Impact factor: 1.810

3.  Structural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virus-related virus protease.

Authors:  Mi Li; Alla Gustchina; Krisztina Matúz; Jozsef Tözsér; Sirilak Namwong; Nathan E Goldfarb; Ben M Dunn; Alexander Wlodawer
Journal:  FEBS J       Date:  2011-10-10       Impact factor: 5.542

Review 4.  Resistance to human immunodeficiency virus type 1 protease inhibitors.

Authors:  D Boden; M Markowitz
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

5.  Identification of folding preferences of cleavage junctions of HIV-1 precursor proteins for regulation of cleavability.

Authors:  Hirotaka Ode; Masaru Yokoyama; Tadahito Kanda; Hironori Sato
Journal:  J Mol Model       Date:  2010-05-18       Impact factor: 1.810

6.  Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.

Authors:  Steve C Pettit; Gavin J Henderson; Celia A Schiffer; Ronald Swanstrom
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.

Authors:  S C Pettit; M D Moody; R S Wehbie; A H Kaplan; P V Nantermet; C A Klein; R Swanstrom
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

Review 8.  Molecular mechanisms of FIV infection.

Authors:  John H Elder; Magnus Sundstrom; Sohela de Rozieres; Aymeric de Parseval; Chris K Grant; Ying-Chuan Lin
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

9.  Structure of equine infectious anemia virus proteinase complexed with an inhibitor.

Authors:  A Gustchina; J Kervinen; D J Powell; A Zdanov; J Kay; A Wlodawer
Journal:  Protein Sci       Date:  1996-08       Impact factor: 6.725

10.  Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site.

Authors:  Helga Eizert; Pálma Bander; Péter Bagossi; Tamás Sperka; Gabriella Miklóssy; Péter Boross; Irene T Weber; József Tözsér
Journal:  J Virol       Date:  2008-08-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.